Michael Gnant, MD: Perspective on Negative Findings With Palbociclib in HR+/HER2– Early Breast Cancer

Michael Gnant, MD, of the Medical University of Vienna, discusses the clinical implications of negative findings from the PALLAS trial, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer and whether any correlative studies hint at patient subgroups that this regimen may benefit.